1. Huang, C, Wang, Y, Li, X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506. doi:10.1016/S0140-6736(20)30183-5
Google Scholar | Crossref | Medline2. Lu, R, Zhao, X, Li, J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395(10224):565-574. doi:10.1016/S0140-6736(20)30251-8
Google Scholar | Crossref3. Xu, Z, Shi, L, Wang, Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8(4):420-422. doi:10.1016/S2213-2600(20)30076-X
Google Scholar | Crossref | Medline4. Villar, J, Confalonieri, M, Pastores, SM, Meduri, GU. Rationale for prolonged corticosteroid treatment in the acute respiratory distress syndrome caused by coronavirus disease 2019. Crit Care Explor. 2020;2(4):e0111. doi:10.1097/cce.0000000000000111
Google Scholar | Crossref | Medline5. Chaudhuri, D, Sasaki, K, Karkar, A, et al. Corticosteroids in COVID-19 and non-COVID-19 ARDS: a systematic review and meta-analysis. Intensive Care Med. 2021;47(5):521-537. doi:10.1007/s00134-021-06394-2
Google Scholar | Crossref | Medline6. Alhazzani, W, Møller, MH, Arabi, YM, et al. Surviving Sepsis Campaign: Guidelines on the Management of Critically Ill Adults with Coronavirus Disease 2019 (COVID - 19). Springer 2020. doi:10.1007/s00134-020-06022-5
Google Scholar7. Villar, J, Ferrando, C, Martínez, D, et al. Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial. Lancet Respir Med. 2020;8(3):267-276. doi:10.1016/S2213-2600(19)30417-5
Google Scholar | Crossref | Medline8. Ferrando, C, Suarez-Sipmann, F, Mellado-Artigas, R, et al. Clinical features, ventilatory management, and outcome of ARDS caused by COVID-19 are similar to other causes of ARDS. Intensive Care Med. 2020;46(12):2200-2211. doi:10.1007/s00134-020-06192-2
Google Scholar | Crossref | Medline9. Prescott, HC, Rice, TW. Corticosteroids in COVID-19 ARDS: evidence and hope during the pandemic. JAMA - J Am Med Assoc. 2020;324(13):1292-1295. doi:10.1001/jama.2020.16747
Google Scholar | Crossref | Medline10. Maskin, LP, Olarte, GL, Palizas, F, et al. High dose dexamethasone treatment for acute respiratory distress syndrome secondary to COVID-19: a structured summary of a study protocol for a randomised controlled trial. Trials. 2020;21(1):20-22. doi:10.1186/s13063-020-04646-y
Google Scholar | Crossref | Medline11. Ranieri, VM, Rubenfeld, GD, Thompson, BT, et al. Acute respiratory distress syndrome: the Berlin definition. JAMA: J Am Med Assoc. 2012;307(23):2526-2533. doi:10.1001/jama.2012.5669
Google Scholar | Medline | ISI12. Harris, PA, Taylor, R, Minor, BL, et al. The REDCap consortium: building an international community of software platform partners. J Biomed Inform. 2019;95(December 2018):103208. doi:10.1016/j.jbi.2019.103208
Google Scholar | Crossref | Medline13. Dexamethasone in hospitalized patients with covid-19. N Engl J Med. 2021;384(8):693-704. doi:10.1056/NEJMoa2021436
Google Scholar | Crossref | Medline14. Papazian, L, Aubron, C. Formal guidelines: management of acute respiratory distress syndrome. Ann Intensive Care. 2019;9(1):69. doi:10.1186/s13613-019-0540-9
Google Scholar | Crossref | Medline15. ARDSNetwork . Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med. 2000;342(18):1301-1308. doi:10.1056/NEJM200005043421801
Google Scholar | Crossref | Medline16. Rodriguez, PO, Tiribelli, N, Fredes, S, et al. Prevalence of reverse triggering in early ARDS: results From a multicenter observational study. Chest. 2021;159(1):186-195. doi:10.1016/j.chest.2020.08.018
Google Scholar | Crossref | Medline17. Carpenter, J, Bithell, J. Bootstrap confidence intervals: when, which, what? A practical guide for medical statisticians. Stat Med. 2000; 19(9):1141-1164. doi:10.1002/(SICI)1097-0258(20000515)19:9<1141::AID-SIM479>3.0.CO;2-F
Google Scholar | Crossref | Medline | ISI18. Zhou, B, Fine, J, Latouche, A, Labopin, M. Competing risks regression for clustered data. Biostatistics. 2012;13(3):371-383. doi:10.1093/biostatistics/kxr032
Google Scholar | Crossref | Medline19. R Core Team . R: A Language and Environment for Statistical Computing. Published online 2019. https://www.r-project.org/
Google Scholar20. Tomazini, BM, Maia, IS, Cavalcanti, AB, et al. Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX randomized clinical trial. JAMA - J Am Med Assoc. 2020;324(13):1307-1316. doi:10.1001/jama.2020.17021
Google Scholar | Crossref | Medline21. Sterne, JAC, Murthy, S, Diaz, JV, et al. Association between administration of systemic corticosteroids and mortality among critically Ill patients with COVID-19: a meta-analysis. JAMA - J Am Med Assoc. 2020;324(13):1330-1341. doi:10.1001/jama.2020.17023
Google Scholar | Crossref | Medline22. Angus, DC, Derde, L, Al-Beidh, F, et al. Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: the REMAP-CAP COVID-19 corticosteroid domain randomized clinical trial. JAMA - J Am Med Assoc. 2020;324(13):1317-1329. doi:10.1001/jama.2020.17022
Google Scholar | Crossref | Medline23. Mellado-Artigas, R, Ferreyro, BL, Angriman, F, et al. High-flow nasal oxygen in patients with COVID-19-associated acute respiratory failure. Crit Care. 2021;25(1):1-10. doi:10.1186/s13054-021-03469-w
Google Scholar | Crossref | Medline24. Spoorenberg, SMC, Deneer, VHM, Grutters, JC, et al. Pharmacokinetics of oral versus intravenous dexamethasone in patients hospitalized with community-acquired pneumonia. Br J Clin Pharmacol. 2014;78(1):78-83. doi:10.1111/bcp.12295
Google Scholar | Crossref | Medline25. Pinzón, MA, Ortiz, S, Holguín, H, et al. Dexamethasone versus methylprednisolone high dose for covid-19 pneumonia. PLoS One. 2021;16(5 May). doi:10.1371/journal.pone.0252057
Google Scholar26. Russell, L, Uhre, KR, Lindgaard, ALS, et al. Effect of 12 mg versus 6 mg of dexamethasone on the number of days alive without life support in adults With COVID-19 and severe hypoxemia. JAMA. 2021;326(18):1807. doi:10.1001/jama.2021.18295
Google Scholar | Crossref | Medline27. Yehya, N, Harhay, MO, Curley, MAQ, Schoenfeld, DA, Reeder, RW. Reappraisal of ventilator-free days in critical care research. Am J Respir Crit Care Med. 2019;200(7):828-836. doi:10.1164/rccm.201810-2050CP
Google Scholar | Crossref | Medline28. Schmidt, M, Hajage, D, Demoule, A, et al. Clinical characteristics and day-90 outcomes of 4244 critically ill adults with COVID-19: a prospective cohort study. Intensive Care Med. 2021;47(1):60-73. doi:10.1007/s00134-020-06294-x
Google Scholar | Crossref | Medline